258 results on '"Studt, Jan-Dirk"'
Search Results
2. Proteomic profiling for biomarker discovery in heparin-induced thrombocytopenia
3. Limited concordance of heparin/platelet factor 4 antibody assays for the diagnosis of heparin-induced thrombocytopenia: an analysis of the TORADI-HIT study
4. Von Willebrand factor and the thrombophilia of severe COVID-19: in situ evidence from autopsies
5. Gerinnungshemmung in Schwangerschaft und Wochenbett
6. Structural analysis of receptors and actin polarity in platelet protrusions
7. Diagnostic Procedures: Coagulation
8. Liver infarctions as the first manifestation of antiphospholipid antibody syndrome in pregnancy: a case report
9. Accuracy of Diagnosing Heparin-Induced Thrombocytopenia
10. Quantifying Residual Rivaroxaban Plasma Concentration after Antagonization with Andexanet Alfa: A Difficult Task in Routine Clinical Practice
11. Successful management of refractory immune‐mediated thrombotic thrombocytopenic purpura during pregnancy and delivery using the anti‐VWF nanobody caplacizumab
12. Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome
13. COagulation MAnagement in Neurosurgical Diseases (COMAND)
14. Challenges in Coagulation Management in Neurosurgical Diseases: A Scoping Review, Development, and Implementation of Coagulation Management Strategies
15. Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome
16. Coagulation Management after Trauma in the Presence of Direct Oral Anticoagulants
17. Développements récents en hématologie, Teil 1
18. Jüngste Entwicklungen in der Hämatologie, Teil 1
19. Grundlagen der Gerinnungsdiagnostik (Thrombophilieabklärung)
20. Determination of Anti-Xa Inhibitor Plasma Concentrations Using a Universal Edoxaban Calibrator
21. Complication rates of peripherally inserted central catheters vs implanted ports in patients receiving systemic anticancer therapy: A retrospective cohort study
22. Limited concordance of heparin/PF4 antibody assays for the diagnosis of heparin-induced thrombocytopenia: an analysis of the TORADI-HIT study
23. Indications and Outcomes of Patients Receiving Therapeutic Plasma Exchange under Critical Care Conditions: A Retrospective Eleven-Year Single-Center Study at a Tertiary Care Center
24. Standard coagulation assays alone are not sufficient to exclude surgically relevant rivaroxaban plasma concentrations
25. Determination of Anti-Xa Inhibitor Plasma Concentrations Using a Universal Edoxaban Calibrator
26. A machine-learning model for reducing misdiagnosis in heparin-induced thrombocytopenia: a prospective, multicenter, observational study
27. Indications and Outcomes of Patients Receiving Therapeutic Plasma Exchange under Critical Care Conditions: A Retrospective Eleven-Year Single-Center Study at a Tertiary Care Center
28. A machine-learning model for reducing misdiagnosis in heparin-induced thrombocytopenia: A prospective, multicenter, observational study
29. Prothrombinase-Induced Clotting Time to Measure Drug Concentrations of Rivaroxaban, Apixaban, and Edoxaban in Clinical Practice: A Cross-Sectional Study
30. Prothrombinase-Induced Clotting Time to Measure Drug Concentrations of Rivaroxaban, Apixaban, and Edoxaban in Clinical Practice: A Cross-Sectional Study
31. The Impact of Prehospital Tranexamic Acid on Blood Coagulation in Trauma Patients
32. Indications and outcomes of patients receiving therapeutic plasma exchange under critical care conditions: a retrospective eleven-year single-center study at a tertiary care center
33. Synthesis of coagulation factors during long-term ex situ liver perfusion
34. Platelets drive fibronectin fibrillogenesis using integrin αIIbβ3
35. Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study
36. Quarantine versus pathogen‐reduced plasma‐coagulation factor content and rotational thromboelastometry coagulation
37. Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study
38. Daratumumab for immune thrombotic thrombocytopenic purpura
39. Reducing Delayed Diagnosis and Overtreatment in Heparin-Induced Thrombocytopenia by Using a Machine-Learning Model: A Prospective, Multicenter, Observational Study
40. Liver infarctions as the first manifestation of antiphospholipid antibody syndrome in pregnancy: a case report
41. Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements
42. COVID‐19 patients often show high‐titer non‐platelet‐activating anti‐PF4/heparin IgG antibodies
43. Synthesis of coagulation factors during long‐term ex situ liver perfusion
44. Thromboembolie veineuse en gynécologie et obstétrique
45. Venöse Thromboembolie in Gynäkologie und Geburtshilfe
46. Ven��se Thromboembolie in Gyn��kologie und Geburtshilfe
47. Dronedarone reduces arterial thrombus formation
48. A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation
49. Thrombotic storm under DOAC treatment in a patient with homozygous antithrombin Budapest III mutation
50. Thrombotisch-thrombozytopene Purpura - differentialdiagnostische Problemstellungen
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.